ArticleCell communication and signaling : CCS2025
Tannic acid inhibits TNF-α signaling by targeting the protein disulfide isomerase and alleviates symptoms in an imiquimod-induced psoriasis mouse model.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- P1D6 inhibits FnBP-induced extracellular proteome remodeling: proteomic evidence for a novel intervention strategy in atopic dermatitis.Molecular medicine (Cambridge, Mass.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundInhibiting TNF-α signaling is an effective approach to prevent inflammation, which can mitigate the symptoms of autoimmune diseases. Activation of the ADAM17-TNFR1 signaling module using small-molecule protein disulfide isomerase (PDI) inhibitors effectively induces TNFR1 shedding and TNF-α signaling inhibition. However, it is not known whether tannic acid (TA), a verified PDI inhibitor with outstanding anti-inflammatory effects, could alleviate autoimmune diseases.
objectiveWe set out to explore the anti-inflammatory mechanism of TA and whether it could be used to treat the classical autoimmune disease, psoriasis.
methodsMolecular interactions were assessed using insulin reduction assays with full-length PDI and its domain fragments to identify TA binding sites. Non-covalent binding and conformational changes were evaluated using AMS-modified SDS-PAGE and ANS fluorescence. Molecular chaperone activity was measured using rhodanese refolding. Cellular assays included cytotoxicity, apoptosis, and NF-κB activation in L929 cells using CCK-8, flow cytometry, western blot, and RT-qPCR. PDI dependency was confirmed using CRISPR-Cas9 knockout. TNFR1 shedding was quantified using flow cytometry and ELISA. In vivo efficacy was tested in an imiquimod (IMQ)-induced psoriasis mouse model treated with TA ointment (5% and 10%), and the outcomes were evaluated using the psoriasis area and severity index (PASI), histopathology, blood routines, and blood biochemical examinations.
resultsTA selectively inhibited the reductase activity of the b’ domain of PDI and induced non-covalent conformational changes, reducing hydrophobicity and chaperone function. TA effectively suppressed TNF-α-induced apoptosis in cells, NF-κB activation, and inflammatory gene expression. PDI knockout abolished TA-induced TNFR1 shedding, confirming PDI dependence. In IMQ-induced psoriatic mice, 10% TA ointment significantly reduced the PASI scores and the incidence of histopathological features. TA also normalized blood inflammation and restored physical functions.
conclusionsIn summary, our study showed that TA blocks TNF-α signaling by inhibiting PDI, and exhibits potential application value in combating autoimmune diseases, especially psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.